SABSW — SAB Biotherapeutics Inc
NASDAQ
$0.03
-$0.00 (-8.64%)
SAB Biotherapeutics Inc (SABSW) common stock listed on NASDAQ. It is led by Samuel J. Reich, based in 777 W 41st St., Miami Beach, FL, United States, 33140, with about 86 employees. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Net income was $45.4M. SABSW currently screens at trailing P/E 0.0.
Use this SABSW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SABSW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SABSW SEC filings page. Lician reads the product cache first so this HTML stays unique to SAB Biotherapeutics Inc even when a live quote feed is slow.
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABSW Key Statistics
Market Cap
$0.00M
Volume
50,324
Previous Close
$0.03
Day Range
$0.03 – $0.04
P/E Ratio
0.05
EPS
-$3.68
Revenue
$1.32M
Net Income
-$34.11M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-40.9%
Profit Margin
-2579.0%
Employees
86
SABSW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $1.32M | $2.24M | $23.90M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$34.11M | -$42.19M | -$18.74M |
| EPS (Diluted) | -$3.68 | -$7.64 | -$4.31 |
Total Assets
$44.20M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$8.90M
Operating Cash Flow
-$34.29M
Free Cash Flow
$0.00
SAB Biotherapeutics Inc Company Information
- CEO & Director
- Samuel J. Reich
- Headquarters
- 777 W 41st St., Miami Beach, FL, United States, 33140
- Website
- www.sab.bio
- Phone
- 305 845 2813
- IPO / Founded
- 2021-02-09